Pharmacovigilance of carmustine: distinct neurotoxic and systemic safety signals identified in FAERS Authors: Kaizhi Xu, Meixuan Guo, Huqiang Dong, Mengyuan Cai, Ping Xu Published: 2026 ABSTRACT BackgroundCarmustine (BCNU), a nitrosourea alkylating agent, is used in malignant gliomas, lymphomas, and hematopoietic stem cell transplantation. Although its major toxicities are recognized, comprehensive postmarketing evidence on the broader spectrum of carmustine related adverse event signals remains limited. This study evaluated carmustine related reporting signals using real world pharmacovigilance data.MethodsAdverse drug reaction (ADR) reports identifying BCNU as the primary suspect were extracted from the FDA Adverse Event Reporting System (FAERS, Q1 2004–Q1 2024). Disproportionality analyses using reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayesian geometric mean (EBGM) were performed at both system organ class (SOC) and preferred term (PT) levels, with stratification by sex.ResultsIn total, 718 BCNU reports with 3,091 preferred terms were analyzed. Significant signals emerged for nervous system disorders (ROR = 2.74), blood and lymphatic system disorders (ROR = 2.95), and infections (ROR = 2.15). At the PT level, eosinophilic meningitis, pneumocephalus, and intracranial hypotension showed strong disproportional reporting signals among carmustine related reports. Descriptive sex stratified reporting patterns were observed, including intracranial hypotension in female reports and pseudomeningocele in male reports.ConclusionCarmustine related FAERS reports showed distinct neurotoxic, hematologic, and procedural reporting patterns, some with descriptive sex specific differences. These findings emphasize the need for continued post-marketing surveillance to inform clinical practice and optimize risk mitigation.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-026-16303-9. Introduction Carmustine, also known as bis-chloroethylnitrosourea or BCNU, is a lipophilic nitrosourea alkylating agent used in several oncologic settings. Clinically, it is used in the treatment of high grade gliomas and lymphomas [1]. It can be administered intravenously or as a local intracranial implant, Gliadel® wafer, after surgical resection in patients with malignant glioma [2, 3]. Carmustine is also widely used in conditioning regimens such as BEAM, which consists of BCNU, etoposide, cytarabine, and melphalan [4], and CBV, which consists of BCNU, etoposide, and cyclophosphamide [5], before autologous hematopoietic stem cell transplantation [6, 7]. As an alkylating agent, carmustine exerts cytotoxic effects through DNA and RNA cross linking and protein carbamoylation, ultimately leading to tumor cell death [8, 9]. Despite its established clinical use, carmustine has a well recognized toxicity profile that includes neurologic, hematologic, pulmonary, and hepatic adverse reactions [10]. In postmarketing surveillance of Gliadel® wafers, cerebral edema occurred in 22.2% of patients, followed by convulsions (9.9%) and impaired wound healing (4.8%), raising concerns about neurotoxicity and delayed recovery [11]. In a retrospective analysis of intravenous carmustine in high grade gliomas, hematologic toxicities such as grade 3 to 4 neutropenia (20%) and thrombocytopenia (23%) were observed, regardless of whether carmustine was combined with bevacizumab [12]. Other case reports have described delayed onset pulmonary toxicity, including large pleural effusions appearing 60 days after transplantation [13]. Preclinical models have also reported hepatic and pulmonary damage induced by carmustine through oxidative stress related mechanisms [14, 15]. The Food and Drug Administration Adverse Event Reporting System (FAERS) is a large, publicly accessible pharmacovigilance database that captures spontaneous reports of adverse events (AEs) from healthcare professionals, consumers, and manufacturers in the postmarketing setting [16]. It supports signal detection through disproportionality analysis tools such as the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi item gamma Poisson shrinker (MGPS). Although the major toxicities of carmustine have been recognized, existing evidence is mainly derived from clinical studies, retrospective cohorts, local wafer surveillance, and individual case reports. A comprehensive real world pharmacovigilance assessment of carmustine across both system organ class (SOC) and preferred term (PT) levels remains limited. In particular, less is known about the broader reporting spectrum of neurotoxic, infectious, procedural, hematologic, and sex stratified safety signals in postmarketing data. Therefore, this study used FAERS data from Q1 2004 to Q1 2024 and applied multiple disproportionality algorithms to characterize carmustine related reporting signals at the SOC and PT levels. By integrating overall and sex stratified analyses, this study aimed to complement the known safety profile of carmustine and provide additional real world evidence for clinical awareness and postmarketing safety surveillance. Materials and methods Participants and data mining in the FAERS database Spontaneous reports of AEs associated with BCNU were retrieved from FAERS, covering the period from the first quarter of 2004 to the first quarter of 2024. The raw dataset comprised three core files: demographic characteristics (DEMO, n = 20,638,235), drug administration records (DRUG, n = 83,553,293), and reported adverse events (REAC, n = 49,695,950). In accordance with the FDA FAERS quarterly data extract documentation, duplicate records were removed using case level identifiers [16]. Specifically, records were sorted by CASEID, FDA_DT, and PRIMARYID. For records with the same CASEID, the report with the most recent FDA_DT was retained. If multiple records had the same CASEID and FDA_DT, the report with the highest PRIMARYID was retained. After this deduplication procedure, duplicate cases (n = 3,522,509) were removed. Reports with incomplete or missing key variables were then excluded. After data cleaning, a total of 17,115,726 unique case reports were retained for analysis. Within this cleaned dataset, AEs specifically associated with BCNU were extracted, 718 cases identified as primary suspected drug reports and 3,091 corresponding preferred terms (PTs) based on the standardized Medical Dictionary for Regulatory Activities (MedDRA) [17]. To assess disproportionality in reporting and identify potential safety signals, we applied four established statistical methods: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) [18]. Additionally, we reviewed report-level characteristics, including patient demographics, primary diagnosis or indication for carmustine use, clinical outcomes, and time to onset of adverse events where available. The primary diagnosis or indication was extracted from the FAERS indication field and manually grouped into clinically relevant categories, including glioblastoma or malignant glioma, other brain tumors, lymphoma, hematopoietic stem cell transplantation or conditioning regimens, other malignancies, and other or unspecified indications. The data extraction and analysis workflow is summarized in Fig. 1.Fig. 1The flow diagram of selecting BCNU- related adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS). Abbreviations: Q1 2004–Q1 2024, from the first quarter of 2004 to the first quarter of 2024; DEMO, patient demographics; DRUG, drug records; REAC, adverse event reports; PS, primary suspected; PT, preferred term; ROR, reporting odds ratio; PRR, proportional reporting ratio; BCPNN, Bayesian confidence propagation neural network; MGPS, multi-item gamma Poisson shrinker The flow diagram of selecting BCNU- related adverse events (AEs) from the FDA Adverse Event Reporting System (FAERS). Abbreviations: Q1 2004–Q1 2024, from the first quarter of 2004 to the first quarter of 2024; DEMO, patient demographics; DRUG, drug records; REAC, adverse event reports; PS, primary suspected; PT, preferred term; ROR, reporting odds ratio; PRR, proportional reporting ratio; BCPNN, Bayesian confidence propagation neural network; MGPS, multi-item gamma Poisson shrinker Statistical analysis Descriptive analysis We performed descriptive analyses to characterize the clinical features of all included case reports. Age at the time of the event was stratified into predefined categories. Additional variables examined included sex, country of report submission, and year of reporting. The onset time was calculated as the interval between the initial administration date of BCNU and the date of AE onset, in order to evaluate the temporal distribution of reported AEs. To assess the severity of outcomes, each case was assigned to one mutually exclusive outcome category. The predefined severity hierarchy was death (DE), life threatening event (LT), disability (DS), required intervention to prevent permanent impairment or damage (RI), hospitalization (HO), and other serious medical events (OT). If multiple outcomes were reported for the same case, only the most severe outcome was retained according to this hierarchy: DE > LT > DS > RI > HO > OT. Disproportional analysis of a pharmacovigilance study Disproportionality analysis was employed to identify potential safety signals by comparing the reporting frequency of AEs for BCNU with that of all other drugs in the FAERS database. This method estimates whether specific drug-event combinations are reported more often than expected under the assumption of independence. Four commonly used algorithms were applied: ROR, PRR, BCPNN, and MGPS. The BCPNN method yields the information component (IC) and its 95% lower confidence limit (IC₀₂₅), while the MGPS method produces the empirical Bayes geometric mean (EBGM) and its 5th percentile (EB₀₅). Signal detection was performed at both the System Organ Class (SOC) and Preferred Term (PT) levels. A signal was considered present when both the lower bound of the 95% confidence interval of the ROR exceeded 1.0, and the IC₀₂₅ value was greater than zero, in accordance with published thresholds [19, 20]. Equations for disproportionate analysis are shown in Supplementary Table S1. In addition, time-to-onset (TTO) was defined as the interval between the date of drug initiation (START_DT, from the THER file) and the onset of the adverse event (EVENT_DT, from the DEMO file). Records with inconsistent or illogical entries (e.g., EVENT_DT earlier than START_DT), or missing date information, were excluded from the TTO analysis. In addition, an exploratory diagnosis-stratified SOC-level disproportionality analysis was performed to assess whether reporting patterns differed across major clinical indication categories. Reports were stratified according to the indication groups defined in the descriptive analysis, including glioblastoma or malignant glioma, other brain/CNS tumors, lymphoma, HSCT or conditioning regimen, other malignancies, and other or unspecified indications. Within each indication stratum, SOC-level disproportionality signals were calculated using the same signal-detection criteria as the main analysis. An exploratory age-stratified SOC-level disproportionality analysis was performed to examine whether SOC-level reporting patterns differed across age groups. Reports were stratified according to the predefined age categories in Table 1, including < 18, 18–45, 45–65, 65–75, and ≥ 75 years. Reports with unknown age were excluded from the age-stratified analysis. Within each age stratum, SOC-level disproportionality signals were calculated using the same signal-detection criteria as the main analysis. This analysis was exploratory and descriptive because some age strata contained limited numbers of reports.Table 1Characteristics of reports associated with BCNU from 2004 Q1–2024 Q1CharacteristicTotalYear 200427 (3.8) 200577 (10.7) 200641 (5.7) 200769 (9.6) 200840 (5.6) 200916 (2.2) 201025 (3.5) 201126 (3.6) 201217 (2.4) 201347 (6.5) 201472 (10.0) 201572 (10.0) 201625 (3.5) 201733 (4.6) 201811 (1.5) 201938 (5.3) 202028 (3.9) 202118 (2.5) 20228 (1.1) 202319 (2.6) 20249 (1.3)Sex Female294 (40.9) Male424 (59.1)Age (years)58.0 (46.0–65.0)Age group (years) < 1812 (1.7) 18–45120 (16.7) 45–65272 (37.9) 65–75113 (15.7) ≥ 7535 (4.9) Unknown166 (23.1)Weight (kg)77.1 (62.0–88.6)Reported indication/primary diagnosis Glioblastoma or malignant glioma332 (46.2) Other brain/CNS tumors92 (12.8) Lymphoma139 (19.4) HSCT or conditioning regimen30 (4.2) Other malignancies16 (2.2) Other or unspecified indications109 (15.2)Outcome (mutually exclusive hierarchy) Death139 (19.4) Life-threatening event59 (8.2) Disability17 (2.4) Required intervention to prevent permanent impairment/damage26 (3.6) Hospitalization284 (39.6) Other serious medical events180 (25.1) Not reported13 (1.8)Reporter country Japan150 (20.9) United States70 (9.7) France59 (8.2) Other countries106 (14.8) Unknown/Not reported333 (46.4)Report source Health professional256 (35.7) Literature0 (0.0) Consumer0 (0.0) Other15 (2.1) Unknown447 (62.3)Route Intravenous187 (26.0) Intracranial/local implant0 (0.0) Other522 (72.7) Unknown9 (1.3)Time to onset (days)16.0 (4.0–49.2)Values are presented as n (%) for categorical variables and median (interquartile range) for continuous variables. For outcomes, each report was assigned to one mutually exclusive category according to the predefined severity hierarchy described in the Materials and methods section Table 1Characteristics of reports associated with BCNU from 2004 Q1–2024 Q1CharacteristicTotalYear 200427 (3.8) 200577 (10.7) 200641 (5.7) 200769 (9.6) 200840 (5.6) 200916 (2.2) 201025 (3.5) 201126 (3.6) 201217 (2.4) 201347 (6.5) 201472 (10.0) 201572 (10.0) 201625 (3.5) 201733 (4.6) 201811 (1.5) 201938 (5.3) 202028 (3.9) 202118 (2.5) 20228 (1.1) 202319 (2.6) 20249 (1.3)Sex Female294 (40.9) Male424 (59.1)Age (years)58.0 (46.0–65.0)Age group (years) < 1812 (1.7) 18–45120 (16.7) 45–65272 (37.9) 65–75113 (15.7) ≥ 7535 (4.9) Unknown166 (23.1)Weight (kg)77.1 (62.0–88.6)Reported indication/primary diagnosis Glioblastoma or malignant glioma332 (46.2) Other brain/CNS tumors92 (12.8) Lymphoma139 (19.4) HSCT or conditioning regimen30 (4.2) Other malignancies16 (2.2) Other or unspecified indications109 (15.2)Outcome (mutually exclusive hierarchy) Death139 (19.4) Life-threatening event59 (8.2) Disability17 (2.4) Required intervention to prevent permanent impairment/damage26 (3.6) Hospitalization284 (39.6) Other serious medical events180 (25.1) Not reported13 (1.8)Reporter country Japan150 (20.9) United States70 (9.7) France59 (8.2) Other countries106 (14.8) Unknown/Not reported333 (46.4)Report source Health professional256 (35.7) Literature0 (0.0) Consumer0 (0.0) Other15 (2.1) Unknown447 (62.3)Route Intravenous187 (26.0) Intracranial/local implant0 (0.0) Other522 (72.7) Unknown9 (1.3)Time to onset (days)16.0 (4.0–49.2)Values are presented as n (%) for categorical variables and median (interquartile range) for continuous variables. For outcomes, each report was assigned to one mutually exclusive category according to the predefined severity hierarchy described in the Materials and methods section Characteristics of reports associated with BCNU from 2004 Q1–2024 Q1 Values are presented as n (%) for categorical variables and median (interquartile range) for continuous variables. For outcomes, each report was assigned to one mutually exclusive category according to the predefined severity hierarchy described in the Materials and methods section Sex-stratified disproportionality analysis To investigate potential sex-based differences in AE signal patterns, we conducted stratified disproportionality analyses at the SOC level. Case reports were categorized by patient sex (male and female), and the same four signal detection algorithms were applied within each stratum. Signals were defined using established thresholds (i.e., lower 95% CI of ROR > 1, and IC025 > 0). Only reports with complete sex information were included in this analysis. Comparative assessment between sexes was used to explore whether certain SOCs demonstrated differential reporting patterns. Sex specific case counts were also summarized for each SOC and PT and added to Tables 2 and 3 to support interpretation of the sex stratified findings. This analysis was descriptive and was not intended to replace formal subgroup comparison or interaction testing.Table 2Disproportionality analysis of AEs associated with BCNU at the system organ class (SOC) level based on the FAERS database (Q1 2004–Q1 2024)SOCCase Reports(F; M)ROR(95% CI)PRR(95% CI)chisqIC(IC025)EBGM(EBGM05)Blood and lymphatic system disorders128 (60; 68)2.95(2.47, 3.52)2.85(2.39, 3.4)156.731.51(1.26)2.85(2.46)Nervous system disorders564 (240; 324)2.74(2.5, 3.01)2.37(2.19, 2.56)489.061.24(1.11)2.37(2.19)Congenital, familial and genetic disorders17 (6; 11)2.37(1.47, 3.82)2.36(1.47, 3.78)13.351.24(0.57)2.36(1.58)Infections and infestations293 (117; 176)2.15(1.91, 2.43)2.02(1.8, 2.27)160.731.02(0.84)2.02(1.83)Respiratory, thoracic and mediastinal disorders206 (80; 126)1.59(1.38, 1.83)1.54(1.34, 1.77)41.410.63(0.42)1.54(1.37)Vascular disorders90 (33; 57)1.52(1.23, 1.87)1.5(1.23, 1.82)15.330.58(0.28)1.5(1.26)Neoplasms benign, malignant and unspecified (incl cysts and polyps)103 (42; 61)1.46(1.2, 1.78)1.44(1.18, 1.75)14.490.53(0.25)1.44(1.23)Cardiac disorders87 (41; 46)1.17(0.95, 1.45)1.17(0.94, 1.45)2.160.22(−0.08)1.17(0.98)Investigations171 (89; 82)0.99(0.85, 1.16)0.99(0.86, 1.14)0.01−0.01(−0.24)0.99(0.87)Injury, poisoning and procedural complications222 (87; 135)0.92(0.8, 1.05)0.92(0.82, 1.03)1.5−0.11(−0.31)0.92(0.82)Hepatobiliary disorders22 (9; 13)0.88(0.58, 1.34)0.88(0.58, 1.33)0.36−0.18(−0.77)0.88(0.62)Eye disorders48 (25; 23)0.87(0.65, 1.15)0.87(0.66, 1.14)0.95−0.2(−0.61)0.87(0.69)Metabolism and nutrition disorders52 (16; 36)0.87(0.66, 1.14)0.87(0.66, 1.14)1.05−0.2(−0.59)0.87(0.69)Immune system disorders23 (10; 13)0.78(0.52, 1.17)0.78(0.52, 1.18)1.43−0.36(−0.94)0.78(0.55)Renal and urinary disorders30 (10; 20)0.61(0.42, 0.87)0.61(0.43, 0.87)7.6−0.71(−1.22)0.61(0.45)General disorders and administration site conditions297 (107; 190)0.58(0.51, 0.66)0.63(0.57, 0.69)79.71−0.67(−0.84)0.63(0.57)Gastrointestinal disorders128 (53; 75)0.52(0.43, 0.62)0.54(0.45, 0.64)55.27−0.89(−1.15)0.54(0.47)Psychiatric disorders66 (19; 47)0.4(0.31, 0.51)0.41(0.32, 0.52)59.32−1.28(−1.63)0.41(0.34)Skin and subcutaneous tissue disorders50 (21; 29)0.32(0.24, 0.43)0.34(0.26, 0.45)69.34−1.57(−1.97)0.34(0.27)Musculoskeletal and connective tissue disorders26 (13; 13)0.17(0.11, 0.24)0.17(0.11, 0.25)108.29−2.52(−3.07)0.17(0.13)Reproductive system and breast disorders4 (4; 0)0.16(0.06, 0.44)0.17(0.06, 0.45)16.93−2.59(−3.86)0.17(0.07)F and M indicate the number of female and male reports, respectivelyAbbreviations: BCNU bis-chloroethylnitrosourea, SOC System Organ Class, ROR Reporting Odds Ratio, PRR Proportional Reporting Ratio, CI Confidence Interval, chisq chi-squared value, IC Information Component, IC025 lower limit of the 95% credibility interval of IC, EBGM Empirical Bayes Geometric Mean, EBGM05 lower 95% confidence limit of EBGMTable 3Signal detection for BCNU at the Preferred Term (PT) level in FAERS databaseSOCPTCase ReportsROR (95% CI)PRR (95% CI)chisqIC(IC025)EBGM(EBGM05)Nervous system disordersmeningitis eosinophilic32337.73(699.27, 7815.28)2335.06(692.7, 7871.41)6159.2811(9.49)2054.97(748.57)Nervous system disordersintracranial hypotension20666.21(425.52, 1043.05)661.15(421.23, 1037.72)12,693.099.31(8.68)636.61(437.49)Nervous system disorderssubdural hygroma4288.23(107.21, 774.88)287.79(108.01, 766.8)1124.38.14(6.87)283.05(123.74)Nervous system disordersbrain oedema109193.56(159.62, 234.7)185.57(155.56, 221.37)19,799.967.52(7.24)183.59(156.25)Nervous system disorderscerebral cyst5147.14(60.96, 355.13)146.86(60.79, 354.77)718.187.19(6.02)145.62(69.67)Nervous system disorderscerebrospinal fluid leakage8102.92(51.31, 206.46)102.61(51.67, 203.76)800.226.67(5.73)102.01(56.98)Nervous system disorderscerebral vasoconstriction383.49(26.84, 259.75)83.39(26.76, 259.91)243.046.37(4.96)83(32.11)Nervous system disordershemiplegia3381.59(57.83, 115.1)80.58(57.75, 112.44)2581.76.33(5.84)80.2(60.14)Nervous system disordershydrocephalus1770.58(43.77, 113.82)70.13(43.81, 112.25)1153.816.13(5.46)69.85(46.83)Nervous system disorderspostictal state357.72(18.57, 179.43)57.66(18.5, 179.71)166.465.84(4.43)57.47(22.25)Nervous system disordersmyelopathy446.13(17.28, 123.17)46.06(17.29, 122.72)175.875.52(4.25)45.94(20.2)Nervous system disorderscerebral haematoma744.36(21.11, 93.24)44.25(21.01, 93.19)295.155.46(4.46)44.14(23.71)Nervous system disordersneurological decompensation441.88(15.69, 111.8)41.82(15.7, 111.43)158.985.38(4.11)41.72(18.34)Nervous system disordersintracranial pressure increased1039.31(21.11, 73.2)39.17(20.92, 73.34)371.115.29(4.43)39.08(23.23)Injury, poisoning and procedural complicationspneumocephalus352851.72(1990.47, 4085.61)2813.76(1977.28, 4004.11)84,523.4711.24(10.73)2416.8(1788.89)Injury, poisoning and procedural complicationspseudomeningocele81164.47(568.46, 2385.39)1160.93(573.28, 2350.95)8682.8310.09(9.11)1087.29(596.71)Injury, poisoning and procedural complicationsmeningitis chemical3292.21(93.28, 915.38)291.88(93.65, 909.73)855.098.16(6.73)287.01(110.4)Injury, poisoning and procedural complicationsprocedural site reaction6236.73(105.67, 530.32)236.19(105.75, 527.55)1386.067.86(6.79)232.99(118.64)Injury, poisoning and procedural complicationsincision site complication9205.64(106.46, 397.21)204.94(107.33, 391.32)1804.927.66(6.76)202.53(116.75)Injury, poisoning and procedural complicationsextradural haematoma7109.76(52.15, 231)109.47(51.98, 230.55)747.576.77(5.76)108.78(58.36)Injury, poisoning and procedural complicationsbrain herniation643.37(19.45, 96.73)43.28(19.38, 96.67)247.25.43(4.36)43.17(22.07)Injury, poisoning and procedural complicationswound dehiscence743.31(20.61, 91.02)43.2(20.51, 90.98)287.825.43(4.43)43.09(23.15)Injury, poisoning and procedural complicationspost procedural complication3538.04(27.24, 53.12)37.55(26.91, 52.4)1242.815.23(4.75)37.47(28.33)Injury, poisoning and procedural complicationswound secretion631.28(14.03, 69.74)31.21(13.97, 69.71)175.144.96(3.89)31.15(15.93)Infections and infestationscns ventriculitis3231.67(74.1, 724.27)231.4(74.24, 721.22)679.057.83(6.41)228.33(87.97)Infections and infestationsbrain abscess21196.68(127.71, 302.91)195.12(126.78, 300.31)4010.027.59(6.98)192.93(134.42)Infections and infestationsextradural abscess4110.11(41.17, 294.53)109.94(41.26, 292.93)429.066.77(5.5)109.25(47.96)Infections and infestationswound infection staphylococcal666.35(29.73, 148.05)66.2(29.64, 147.86)383.826.04(4.97)65.95(33.69)Infections and infestationscentral nervous system infection362.72(20.17, 194.99)62.65(20.1, 195.27)181.335.96(4.55)62.42(24.16)Infections and infestationsescherichia bacteraemia331.47(10.13, 97.75)31.44(10.09, 97.99)88.254.97(3.56)31.38(12.16)Infections and infestationsmeningitis930.3(15.74, 58.32)30.19(15.81, 57.65)253.634.91(4.02)30.14(17.42)Infections and infestationspurulence329.06(9.36, 90.23)29.02(9.31, 90.45)81.044.86(3.44)28.98(11.23)Infections and infestationspostoperative wound infection826.23(13.1, 52.53)26.15(13.17, 51.93)193.264.71(3.76)26.11(14.6)Investigationscsf culture positive51033.52(418.78, 2550.61)1031.55(418.73, 2541.27)4855.299.93(8.73)973(456.92)Investigationsbrain scan abnormal4141.73(52.94, 379.45)141.52(53.11, 377.07)553.537.13(5.86)140.37(61.58)Investigationscsf test abnormal3130.2(41.79, 405.7)130.05(41.73, 405.34)381.297.01(5.59)129.08(49.87)Investigationsculture positive489.79(33.59, 240.03)89.65(33.65, 238.87)348.846.48(5.21)89.19(39.17)Investigationsstaphylococcus test positive328.57(9.2, 88.73)28.54(9.16, 88.95)79.594.83(3.42)28.49(11.04)Neoplasms benign, malignant and unspecified (incl cysts and polyps)malignant glioma4666.01(245.12, 1809.65)665(244.74, 1806.93)2552.879.32(8.03)640.18(277.37)Neoplasms benign, malignant and unspecified (incl cysts and polyps)glioblastoma multiforme5120.99(50.16, 291.82)120.76(49.99, 291.72)589.696.91(5.75)119.92(57.4)Neoplasms benign, malignant and unspecified (incl cysts and polyps)diffuse large b-cell lymphoma recurrent347.84(15.4, 148.67)47.79(15.33, 148.95)137.055.57(4.16)47.66(18.45)Neoplasms benign, malignant and unspecified (incl cysts and polyps)neoplasm recurrence534.04(14.14, 81.92)33.98(14.07, 82.09)159.725.08(3.93)33.91(16.26)General disorders and administration site conditionsimplant site oedema51021.21(413.93, 2519.47)1019.27(413.74, 2511.01)4800.629.91(8.72)962.07(451.9)General disorders and administration site conditionsimplant site reaction4163.72(61.11, 438.59)163.47(61.35, 435.56)639.817.34(6.07)161.94(71)Eye disorderspupil fixed445.34(16.98, 121.05)45.27(16.99, 120.62)172.725.5(4.23)45.15(19.85)Eye disordersconjunctival haemorrhage739.44(18.77, 82.89)39.34(18.68, 82.85)260.975.29(4.29)39.25(21.09)Vascular disordersvenoocclusive disease341.85(13.47, 130.01)41.8(13.41, 130.28)119.185.38(3.96)41.7(16.15)Respiratory, thoracic and mediastinal disorderspulmonary toxicity934.34(17.84, 66.11)34.22(17.92, 65.34)289.745.09(4.2)34.16(19.74)Congenital, familial and genetic disordersaplasia15141.47(84.99, 235.49)140.67(84.51, 234.16)2063.247.12(6.41)139.53(91.09)Blood and lymphatic system disordersfebrile bone marrow aplasia951.72(26.85, 99.61)51.54(26.99, 98.41)444.755.68(4.79)51.39(29.7)Abbreviations: BCNU bis-chloroethylnitrosourea, SOC System Organ Class, PT Preferred Term, ROR Reporting Odds Ratio, PRR Proportional Reporting Ratio, CI Confidence Interval, chisq chi-squared value, IC Information Component, IC025 lower limit of the 95% credibility interval of IC, EBGM Empirical Bayes Geometric Mean, EBGM05 lower 95% confidence limit of EBGM Table 2Disproportionality analysis of AEs associated with BCNU at the system organ class (SOC) level based on the FAERS database (Q1 2004–Q1 2024)SOCCase Reports(F; M)ROR(95% CI)PRR(95% CI)chisqIC(IC025)EBGM(EBGM05)Blood and lymphatic system disorders128 (60; 68)2.95(2.47, 3.52)2.85(2.39, 3.4)156.731.51(1.26)2.85(2.46)Nervous system disorders564 (240; 324)2.74(2.5, 3.01)2.37(2.19, 2.56)489.061.24(1.11)2.37(2.19)Congenital, familial and genetic disorders17 (6; 11)2.37(1.47, 3.82)2.36(1.47, 3.78)13.351.24(0.57)2.36(1.58)Infections and infestations293 (117; 176)2.15(1.91, 2.43)2.02(1.8, 2.27)160.731.02(0.84)2.02(1.83)Respiratory, thoracic and mediastinal disorders206 (80; 126)1.59(1.38, 1.83)1.54(1.34, 1.77)41.410.63(0.42)1.54(1.37)Vascular disorders90 (33; 57)1.52(1.23, 1.87)1.5(1.23, 1.82)15.330.58(0.28)1.5(1.26)Neoplasms benign, malignant and unspecified (incl cysts and polyps)103 (42; 61)1.46(1.2, 1.78)1.44(1.18, 1.75)14.490.53(0.25)1.44(1.23)Cardiac disorders87 (41; 46)1.17(0.95, 1.45)1.17(0.94, 1.45)2.160.22(−0.08)1.17(0.98)Investigations171 (89; 82)0.99(0.85, 1.16)0.99(0.86, 1.14)0.01−0.01(−0.24)0.99(0.87)Injury, poisoning and procedural complications222 (87; 135)0.92(0.8, 1.05)0.92(0.82, 1.03)1.5−0.11(−0.31)0.92(0.82)Hepatobiliary disorders22 (9; 13)0.88(0.58, 1.34)0.88(0.58, 1.33)0.36−0.18(−0.77)0.88(0.62)Eye disorders48 (25; 23)0.87(0.65, 1.15)0.87(0.66, 1.14)0.95−0.2(−0.61)0.87(0.69)Metabolism and nutrition disorders52 (16; 36)0.87(0.66, 1.14)0.87(0.66, 1.14)1.05−0.2(−0.59)0.87(0.69)Immune system disorders23 (10; 13)0.78(0.52, 1.17)0.78(0.52, 1.18)1.43−0.36(−0.94)0.78(0.55)Renal and urinary disorders30 (10; 20)0.61(0.42, 0.87)0.61(0.43, 0.87)7.6−0.71(−1.22)0.61(0.45)General disorders and administration site conditions297 (107; 190)0.58(0.51, 0.66)0.63(0.57, 0.69)79.71−0.67(−0.84)0.63(0.57)Gastrointestinal disorders128 (53; 75)0.52(0.43, 0.62)0.54(0.45, 0.64)55.27−0.89(−1.15)0.54(0.47)Psychiatric disorders66 (19; 47)0.4(0.31, 0.51)0.41(0.32, 0.52)59.32−1.28(−1.63)0.41(0.34)Skin and subcutaneous tissue disorders50 (21; 29)0.32(0.24, 0.43)0.34(0.26, 0.45)69.34−1.57(−1.97)0.34(0.27)Musculoskeletal and connective tissue disorders26 (13; 13)0.17(0.11, 0.24)0.17(0.11, 0.25)108.29−2.52(−3.07)0.17(0.13)Reproductive system and breast disorders4 (4; 0)0.16(0.06, 0.44)0.17(0.06, 0.45)16.93−2.59(−3.86)0.17(0.07)F and M indicate the number of female and male reports, respectivelyAbbreviations: BCNU bis-chloroethylnitrosourea, SOC System Organ Class, ROR Reporting Odds Ratio, PRR Proportional Reporting Ratio, CI Confidence Interval, chisq chi-squared value, IC Information Component, IC025 lower limit of the 95% credibility interval of IC, EBGM Empirical Bayes Geometric Mean, EBGM05 lower 95% confidence limit of EBGM Disproportionality analysis of AEs associated with BCNU at the system organ class (SOC) level based on the FAERS database (Q1 2004–Q1 2024) F and M indicate the number of female and male reports, respectively Abbreviations: BCNU bis-chloroethylnitrosourea, SOC System Organ Class, ROR Reporting Odds Ratio, PRR Proportional Reporting Ratio, CI Confidence Interval, chisq chi-squared value, IC Information Component, IC025 lower limit of the 95% credibility interval of IC, EBGM Empirical Bayes Geometric Mean, EBGM05 lower 95% confidence limit of EBGM Table 3Signal detection for BCNU at the Preferred Term (PT) level in FAERS databaseSOCPTCase ReportsROR (95% CI)PRR (95% CI)chisqIC(IC025)EBGM(EBGM05)Nervous system disordersmeningitis eosinophilic32337.73(699.27, 7815.28)2335.06(692.7, 7871.41)6159.2811(9.49)2054.97(748.57)Nervous system disordersintracranial hypotension20666.21(425.52, 1043.05)661.15(421.23, 1037.72)12,693.099.31(8.68)636.61(437.49)Nervous system disorderssubdural hygroma4288.23(107.21, 774.88)287.79(108.01, 766.8)1124.38.14(6.87)283.05(123.74)Nervous system disordersbrain oedema109193.56(159.62, 234.7)185.57(155.56, 221.37)19,799.967.52(7.24)183.59(156.25)Nervous system disorderscerebral cyst5147.14(60.96, 355.13)146.86(60.79, 354.77)718.187.19(6.02)145.62(69.67)Nervous system disorderscerebrospinal fluid leakage8102.92(51.31, 206.46)102.61(51.67, 203.76)800.226.67(5.73)102.01(56.98)Nervous system disorderscerebral vasoconstriction383.49(26.84, 259.75)83.39(26.76, 259.91)243.046.37(4.96)83(32.11)Nervous system disordershemiplegia3381.59(57.83, 115.1)80.58(57.75, 112.44)2581.76.33(5.84)80.2(60.14)Nervous system disordershydrocephalus1770.58(43.77, 113.82)70.13(43.81, 112.25)1153.816.13(5.46)69.85(46.83)Nervous system disorderspostictal state357.72(18.57, 179.43)57.66(18.5, 179.71)166.465.84(4.43)57.47(22.25)Nervous system disordersmyelopathy446.13(17.28, 123.17)46.06(17.29, 122.72)175.875.52(4.25)45.94(20.2)Nervous system disorderscerebral haematoma744.36(21.11, 93.24)44.25(21.01, 93.19)295.155.46(4.46)44.14(23.71)Nervous system disordersneurological decompensation441.88(15.69, 111.8)41.82(15.7, 111.43)158.985.38(4.11)41.72(18.34)Nervous system disordersintracranial pressure increased1039.31(21.11, 73.2)39.17(20.92, 73.34)371.115.29(4.43)39.08(23.23)Injury, poisoning and procedural complicationspneumocephalus352851.72(1990.47, 4085.61)2813.76(1977.28, 4004.11)84,523.4711.24(10.73)2416.8(1788.89)Injury, poisoning and procedural complicationspseudomeningocele81164.47(568.46, 2385.39)1160.93(573.28, 2350.95)8682.8310.09(9.11)1087.29(596.71)Injury, poisoning and procedural complicationsmeningitis chemical3292.21(93.28, 915.38)291.88(93.65, 909.73)855.098.16(6.73)287.01(110.4)Injury, poisoning and procedural complicationsprocedural site reaction6236.73(105.67, 530.32)236.19(105.75, 527.55)1386.067.86(6.79)232.99(118.64)Injury, poisoning and procedural complicationsincision site complication9205.64(106.46, 397.21)204.94(107.33, 391.32)1804.927.66(6.76)202.53(116.75)Injury, poisoning and procedural complicationsextradural haematoma7109.76(52.15, 231)109.47(51.98, 230.55)747.576.77(5.76)108.78(58.36)Injury, poisoning and procedural complicationsbrain herniation643.37(19.45, 96.73)43.28(19.38, 96.67)247.25.43(4.36)43.17(22.07)Injury, poisoning and procedural complicationswound dehiscence743.31(20.61, 91.02)43.2(20.51, 90.98)287.825.43(4.43)43.09(23.15)Injury, poisoning and procedural complicationspost procedural complication3538.04(27.24, 53.12)37.55(26.91, 52.4)1242.815.23(4.75)37.47(28.33)Injury, poisoning and procedural complicationswound secretion631.28(14.03, 69.74)31.21(13.97, 69.71)175.144.96(3.89)31.15(15.93)Infections and infestationscns ventriculitis3231.67(74.1, 724.27)231.4(74.24, 721.22)679.057.83(6.41)228.33(87.97)Infections and infestationsbrain abscess21196.68(127.71, 302.91)195.12(126.78, 300.31)4010.027.59(6.98)192.93(134.42)Infections and infestationsextradural abscess4110.11(41.17, 294.53)109.94(41.26, 292.93)429.066.77(5.5)109.25(47.96)Infections and infestationswound infection staphylococcal666.35(29.73, 148.05)66.2(29.64, 147.86)383.826.04(4.97)65.95(33.69)Infections and infestationscentral nervous system infection362.72(20.17, 194.99)62.65(20.1, 195.27)181.335.96(4.55)62.42(24.16)Infections and infestationsescherichia bacteraemia331.47(10.13, 97.75)31.44(10.09, 97.99)88.254.97(3.56)31.38(12.16)Infections and infestationsmeningitis930.3(15.74, 58.32)30.19(15.81, 57.65)253.634.91(4.02)30.14(17.42)Infections and infestationspurulence329.06(9.36, 90.23)29.02(9.31, 90.45)81.044.86(3.44)28.98(11.23)Infections and infestationspostoperative wound infection826.23(13.1, 52.53)26.15(13.17, 51.93)193.264.71(3.76)26.11(14.6)Investigationscsf culture positive51033.52(418.78, 2550.61)1031.55(418.73, 2541.27)4855.299.93(8.73)973(456.92)Investigationsbrain scan abnormal4141.73(52.94, 379.45)141.52(53.11, 377.07)553.537.13(5.86)140.37(61.58)Investigationscsf test abnormal3130.2(41.79, 405.7)130.05(41.73, 405.34)381.297.01(5.59)129.08(49.87)Investigationsculture positive489.79(33.59, 240.03)89.65(33.65, 238.87)348.846.48(5.21)89.19(39.17)Investigationsstaphylococcus test positive328.57(9.2, 88.73)28.54(9.16, 88.95)79.594.83(3.42)28.49(11.04)Neoplasms benign, malignant and unspecified (incl cysts and polyps)malignant glioma4666.01(245.12, 1809.65)665(244.74, 1806.93)2552.879.32(8.03)640.18(277.37)Neoplasms benign, malignant and unspecified (incl cysts and polyps)glioblastoma multiforme5120.99(50.16, 291.82)120.76(49.99, 291.72)589.696.91(5.75)119.92(57.4)Neoplasms benign, malignant and unspecified (incl cysts and polyps)diffuse large b-cell lymphoma recurrent347.84(15.4, 148.67)47.79(15.33, 148.95)137.055.57(4.16)47.66(18.45)Neoplasms benign, malignant and unspecified (incl cysts and polyps)neoplasm recurrence534.04(14.14, 81.92)33.98(14.07, 82.09)159.725.08(3.93)33.91(16.26)General disorders and administration site conditionsimplant site oedema51021.21(413.93, 2519.47)1019.27(413.74, 2511.01)4800.629.91(8.72)962.07(451.9)General disorders and administration site conditionsimplant site reaction4163.72(61.11, 438.59)163.47(61.35, 435.56)639.817.34(6.07)161.94(71)Eye disorderspupil fixed445.34(16.98, 121.05)45.27(16.99, 120.62)172.725.5(4.23)45.15(19.85)Eye disordersconjunctival haemorrhage739.44(18.77, 82.89)39.34(18.68, 82.85)260.975.29(4.29)39.25(21.09)Vascular disordersvenoocclusive disease341.85(13.47, 130.01)41.8(13.41, 130.28)119.185.38(3.96)41.7(16.15)Respiratory, thoracic and mediastinal disorderspulmonary toxicity934.34(17.84, 66.11)34.22(17.92, 65.34)289.745.09(4.2)34.16(19.74)Congenital, familial and genetic disordersaplasia15141.47(84.99, 235.49)140.67(84.51, 234.16)2063.247.12(6.41)139.53(91.09)Blood and lymphatic system disordersfebrile bone marrow aplasia951.72(26.85, 99.61)51.54(26.99, 98.41)444.755.68(4.79)51.39(29.7)Abbreviations: BCNU bis-chloroethylnitrosourea, SOC System Organ Class, PT Preferred Term, ROR Reporting Odds Ratio, PRR Proportional Reporting Ratio, CI Confidence Interval, chisq chi-squared value, IC Information Component, IC025 lower limit of the 95% credibility interval of IC, EBGM Empirical Bayes Geometric Mean, EBGM05 lower 95% confidence limit of EBGM Signal detection for BCNU at the Preferred Term (PT) level in FAERS database Abbreviations: BCNU bis-chloroethylnitrosourea, SOC System Organ Class, PT Preferred Term, ROR Reporting Odds Ratio, PRR Proportional Reporting Ratio, CI Confidence Interval, chisq chi-squared value, IC Information Component, IC025 lower limit of the 95% credibility interval of IC, EBGM Empirical Bayes Geometric Mean, EBGM05 lower 95% confidence limit of EBGM All data extraction, cleaning, statistical analyses, and visualization were performed using R software version 4.3.2. Data management and preprocessing were conducted using the data.table, dplyr, tidyr, stringr, and lubridate packages. Disproportionality indices, including ROR, PRR, IC, and EBGM, were calculated using custom R scripts based on standard two-by-two contingency tables and published pharmacovigilance signal-detection formulas. Figures were generated using the ggplot2 package, and tables were exported and formatted using the openxlsx package. The study was designed and reported in accordance with current recommendations for pharmacology epidemiological research using spontaneous reporting databases such as FAERS. Results Descriptive analysis A total of 718 reports listing BCNU as the primary suspected drug were retrieved from FAERS between Q1 2004 and Q1 2024. Report frequency was highest in 2005, 2014, and 2015. Male patients accounted for 59.1% of reports, and the median age was 58.0 years (IQR: 46.0–65.0). The largest age group was 45–65 years (37.9%), and age information was unknown in 23.1% of reports. Reported indications mainly reflected neuro-oncologic and hematologic treatment settings. The most frequent indication was glioblastoma or malignant glioma (46.2%), followed by lymphoma (19.4%), other brain/CNS tumors (12.8%), other or unspecified indications (15.2%), HSCT or conditioning regimen (4.2%), and other malignancies (2.2%). According to the mutually exclusive outcome hierarchy, hospitalization was the most frequent outcome (39.6%), followed by other serious medical events (25.1%), death (19.4%), life-threatening events (8.2%), required intervention to prevent permanent impairment or damage (3.6%), and disability (2.4%). Reporter country was unknown or not reported in 46.4% of cases. Among available country records, Japan was the most frequently reported country (20.9%), followed by the United States (9.7%) and France (8.2%). The intravenous route was reported in 26.0% of cases, and the median time to onset was 16.0 days (IQR: 4.0–49.2) (Table 1). SOC level reporting signals for carmustine ranked by the reporting odds ratio algorithm Disproportionality analysis based on FAERS data from Q1 2004 to Q1 2024 identified several system organ classes (SOCs) with elevated reporting frequencies among carmustine related reports (Table 2). The strongest signal was observed in “blood and lymphatic system disorders” (ROR = 2.95, 95% CI: 2.47–3.52; IC025 = 1.26), followed by “nervous system disorders” (ROR = 2.74, 95% CI: 2.50–3.01; IC025 = 1.11) and “congenital, familial and genetic disorders” (ROR = 2.37, 95% CI: 1.47–3.82; IC025 = 0.57). Other SOCs showing positive signals included “infections and infestations” (ROR = 2.15, IC025 = 0.84), “respiratory, thoracic and mediastinal disorders” (ROR = 1.59, IC025 = 0.42), “vascular disorders” (ROR = 1.52, IC025 = 0.28), and “neoplasms benign, malignant and unspecified” (ROR = 1.46, IC025 = 0.25). In contrast, most other SOCs showed no significant disproportionality signals. Notably, “musculoskeletal and connective tissue disorders” and “reproductive system and breast disorders” showed the lowest signal values (ROR = 0.17 and 0.16, IC025 = − 3.07 and − 3.86, respectively). To further explore whether SOC-level reporting patterns differed across clinical indication categories, we performed an exploratory diagnosis-stratified disproportionality analysis. In reports with glioblastoma or malignant glioma, positive signals were mainly observed for nervous system disorders, infections and infestations, vascular disorders, and injury, poisoning and procedural complications. A similar nervous-system-dominant pattern was observed in reports with other brain/CNS tumors. In contrast, lymphoma-related reports showed stronger signals for blood and lymphatic system disorders, cardiac disorders, respiratory, thoracic and mediastinal disorders, and infections and infestations. Reports related to HSCT or conditioning regimens showed positive signals for blood and lymphatic system disorders, respiratory, thoracic and mediastinal disorders, immune system disorders, renal and urinary disorders, and infections and infestations (Supplementary Table S2). We also performed an exploratory age-stratified SOC-level disproportionality analysis. Nervous system disorders remained a positive reporting signal across all age strata. In the < 18 years group, positive signals were observed for neoplasms benign, malignant and unspecified and nervous system disorders. In the 18–45 years group, positive signals were observed for nervous system disorders, eye disorders, blood and lymphatic system disorders, and neoplasms benign, malignant and unspecified. In the 45–65 years group, positive signals were observed for blood and lymphatic system disorders, nervous system disorders, infections and infestations, neoplasms, and vascular disorders. In the 65–75 years group, nervous system disorders, infections and infestations, blood and lymphatic system disorders, and metabolism and nutrition disorders showed positive signals. In the ≥ 75 years group, positive signals were observed for nervous system disorders, cardiac disorders, and infections and infestations (Supplementary Table S3). Sex stratified SOC level reporting signals for carmustine When stratified by sex, nervous system disorders showed the strongest and most consistent signal in both subgroups (female ROR: 2.80, 95% CI: 2.42–3.23; male ROR: 2.76, 95% CI: 2.44–3.12). Blood and lymphatic system disorders also showed positive reporting signals in both sexes, with descriptively higher disproportionality in females. Congenital, familial and genetic disorders showed positive reporting signals in both sexes despite small sample sizes, with only minor descriptive differences between female and male reports (IC025: 0.22 vs. 0.20). Respiratory and vascular disorders showed positive reporting signals in both sexes, although the signal strength was moderate. Several SOCs showed descriptive differences between female and male reports. Investigations showed a positive reporting signal only in females (IC025: 0.12), whereas males showed a negative signal (IC025: –0.78). Cardiac disorders showed a signal in females (ROR: 1.64), but not in males. In contrast, general disorders, gastrointestinal disorders, psychiatric disorders, and musculoskeletal disorders showed lower than expected reporting in both sexes, with musculoskeletal disorders showing the lowest descriptive signal values (female IC025: −3.15; male IC025: −3.23) (Supplementary Table S4). PT level reporting signals in carmustine related adverse event reports At the preferred term (PT) level, our disproportionality analysis identified several PTs with strong disproportional reporting among carmustine related reports. The top 50 PTs, ranked by ROR, are summarized in Table 3. Among nervous system disorders, eosinophilic meningitis showed an extremely high disproportionality, with a ROR of 2337.73 (95% CI: 699.27–7815.28) and IC025 of 9.49, despite only three reported cases. Similarly, intracranial hypotension (n = 20) and subdural hygroma (n = 4) presented robust signals, with RORs of 666.21 and 288.23, and corresponding IC025 values of 8.68 and 6.87, respectively. Common neurological events such as brain oedema (n = 109, IC025 = 7.24) and hydrocephalus (n = 17, IC025 = 5.46) also showed positive disproportional reporting. To complement signal-based rankings, we visualized the distribution of PT-level reports (Fig. 2).Fig. 2Proportion of carmustine-associated adverse events by preferred term (PT), categorized by system organ class (SOC). Horizontal bars represent the percentage of total glibenclamide adverse event reports attributed to each PT, with case counts shown alongside. Colors denote the corresponding SOCs Proportion of carmustine-associated adverse events by preferred term (PT), categorized by system organ class (SOC). Horizontal bars represent the percentage of total glibenclamide adverse event reports attributed to each PT, with case counts shown alongside. Colors denote the corresponding SOCs A substantial cluster of reporting signals was also identified within the “injury, poisoning, and procedural complications” category. The most striking example was pneumocephalus (n = 35), which showed the highest IC025 value of 10.73 and an ROR exceeding 2800. Additional PTs such as pseudomeningocele, chemical meningitis, and procedural site reaction also showed strong disproportional reporting, with IC025 values ranging from 6.73 to 9.11. In the category of infections, particularly those involving the central nervous system, multiple strong reporting signals were observed. Brain abscess (n = 21) and ventriculitis (n = 3) yielded IC025 values of 6.98 and 6.41, respectively, indicating disproportionate reporting of central nervous system infections in this dataset. Inflammatory and purulent responses such as meningitis, purulence, and wound infection (staphylococcal) were also frequently reported. Furthermore, positive signals were identified in the domain of diagnostic investigations. For example, CSF culture positive (n = 5) showed a ROR of over 1000 and an IC025 of 8.73, which was consistent with the reporting pattern of central nervous system infection related terms. Other diagnostic PTs, such as brain scan abnormality, CSF test abnormality, and culture positive, showed a similar reporting pattern. Signals were also detected in oncology-related PTs. Malignant glioma and glioblastoma multiforme, both being known indications for BCNU, yielded high RORs and strong positive IC values. While these may reflect underlying disease rather than adverse reactions per se, their appearance reinforces the therapeutic context in which BCNU is used. Similarly, implant site oedema (IC025 = 8.72) and implant site reaction (IC025 = 6.07) were observed and may reflect the treatment context of local carmustine wafer implantation. Finally, though less frequent, vascular, respiratory, and hematologic events also demonstrated notable signals, including veno-occlusive disease, pulmonary toxicity, and febrile bone marrow aplasia. Sex stratified disproportionality analysis identified brain oedema and pneumocephalus as reporting signals in both sexes, with descriptively higher signal values in male reports for both terms. Intracranial hypotension and brain abscess were detected only in female reports, whereas pseudomeningocele and hemiplegia were detected only in male reports, although these PT level findings should be interpreted cautiously because of limited case numbers (Fig. 3).Fig. 3Volcano plot of BCNU-related adverse events stratified by sex Volcano plot of BCNU-related adverse events stratified by sex Discussion This pharmacovigilance study used two decades of FAERS data to characterize carmustine related reporting signals at both SOC and PT levels. The analysis complements the established safety profile of carmustine by providing a broader postmarketing overview that includes recognized hematologic and neurologic toxicities, as well as less frequently described CNS infectious, procedural, diagnostic, and sex stratified reporting patterns. Given the nature of spontaneous reporting data, these findings should be interpreted as reporting signals that require clinical contextualization rather than direct evidence of causality. The reported indications also provide important context for interpreting the safety signals. Carmustine related reports mainly reflected neuro oncologic and hematologic treatment settings, including malignant glioma, lymphoma, and hematopoietic stem cell transplantation or conditioning regimens. The reporting profile may therefore differ across these clinical contexts. In neuro oncologic indications, nervous system and procedural signals may be influenced by intracranial tumor burden, surgical resection, local wafer implantation, cerebrospinal fluid exposure, and postoperative care. In lymphoma or transplantation related indications, blood and lymphatic system disorders and infections may be more closely related to intensive conditioning regimens, marrow suppression, immune compromise, and concomitant therapies. These patterns should be interpreted as clinical context for FAERS reporting signals rather than evidence of diagnosis specific causal effects. Hematologic toxicity remained a predominant reporting pattern. Blood and lymphatic system disorders showed the strongest SOC level signal, which is consistent with prior clinical evidence of grade 3 to 4 neutropenia and thrombocytopenia in carmustine treated patients [12]. This finding supports continued attention to marrow suppression in both neuro oncologic and transplant related treatment settings. Neurologic and CNS related events represented another major reporting pattern in our analysis. Although cerebral edema and seizures have been described after Gliadel® wafer placement [21, 22], our FAERS analysis highlighted additional signals such as pneumocephalus, eosinophilic meningitis, subdural hygroma, and intracranial hypotension. These events should be interpreted in the context of intracranial tumor burden, neurosurgical procedures, local wafer implantation, cerebrospinal fluid exposure, and postoperative care. Pulmonary and hepatic events, including pulmonary toxicity and veno occlusive disease, were also detected among the PT level signals, but these findings were less prominent than the neurologic, infectious, procedural, and hematologic patterns [13]. Therefore, these systemic signals are best interpreted as part of the broader reporting spectrum rather than as the central focus of this study. CNS infection related PTs, including brain abscess, ventriculitis, and positive CSF culture, also showed notable reporting signals. These findings may reflect the clinical context of intracranial treatment, including surgical exposure, local wafer implantation, cerebrospinal fluid leakage, and postoperative monitoring. Because FAERS does not provide sufficient detail on surgical timing, prophylactic antibiotic use, or baseline infection risk, these signals should be interpreted as clinically relevant reporting patterns rather than direct evidence that carmustine independently increases CNS infection risk. These findings echo previous reports where surgical-site infections complicated glioma therapy despite antibiotic prophylaxis [23]. The signal for congenital, familial and genetic disorders should also be interpreted cautiously. At the PT level, this SOC was mainly represented by aplasia, with a limited number of reports. Therefore, this finding may reflect underlying oncologic conditions, treatment related marrow suppression, or nonspecific coding in spontaneous reports rather than a distinct congenital or genetic toxicity profile. Similarly, vascular disorder signals may be influenced by baseline disease characteristics, supportive care, comorbidities, and concomitant therapies. These interpretations remain descriptive and should not be considered mechanistic conclusions [24]. Sex stratified analyses suggested descriptive differences in reporting patterns, including intracranial hypotension in female reports and pseudomeningocele in male reports. These differences may reflect biological factors, treatment context, reporting patterns, or small case numbers within specific PTs. Therefore, the sex stratified findings should be considered hypothesis generating and should not be interpreted as evidence of sex specific susceptibility or causality. Formal subgroup comparisons or interaction analyses in datasets with more complete clinical information are needed to determine whether true sex related differences exist. Strengths of this study include the use of FAERS, a robust real-world pharmacovigilance database capturing a breadth of clinical practice settings, and comprehensive integration with recent clinical, pharmacokinetic, and preclinical findings. This dual approach allows not only identification of frequently reported toxicities but also contextualizes them within evolving treatment strategies and mechanistic insights. Limitations Several limitations of this study warrant consideration. First, the FAERS database relies on spontaneous reporting, which is subject to underreporting, selective reporting, and potential duplication, despite our application of FDA-recommended deduplication procedures. Second, the absence of a true denominator precludes estimation of incidence rates or relative risks, and signal strength may be influenced by variations in drug usage patterns over time. Third, clinical details such as dose, treatment duration, comorbidities, and concomitant therapies are frequently incomplete or inconsistently recorded, limiting our ability to adjust for important confounders. Fourth, the disproportionality analysis methodology identifies statistical associations but cannot infer causal relationships. Some signals, particularly those based on a small number of cases or with wide confidence intervals, may represent noise rather than true adverse drug reactions. Lastly, although we conducted sex stratified analyses, these analyses were descriptive and were not designed to establish sex specific susceptibility or causal differences between female and male reports. Further formal subgroup comparisons or interaction analyses were not feasible because detailed clinical information was frequently missing or incomplete in FAERS. In addition, the primary diagnosis or indication for carmustine use was obtained from reporter submitted FAERS fields, which may be incomplete, inconsistently coded, or nonspecific. Therefore, indication data were used primarily to describe the clinical context of the reports rather than to estimate diagnosis specific adverse event risks. Conclusion In this large scale FAERS based pharmacovigilance study, carmustine related reports showed strong disproportionality signals for established events such as brain edema and hydrocephalus, as well as less frequently reported events including intracranial hypotension and central nervous system infections. These prominent neurotoxicity related signals, observed in both sexes, indicate that intracranial pressure regulation and cerebrospinal fluid dynamics warrant closer clinical attention in carmustine treated patients. Infections, hematologic disorders, and implant related complications also showed notable reporting signals. Several adverse events showed descriptive sex stratified reporting patterns, such as pseudomeningocele in male reports and intracranial hypotension in female reports, but these findings require confirmation in datasets suitable for formal subgroup comparison. These findings support ongoing post-marketing surveillance for BCNU, particularly given its continued use in high-risk neuro-oncologic and transplant settings. Prospective studies are warranted to confirm these signals and inform tailored monitoring strategies in clinical practice. Supplementary Information Supplementary Material 1. Supplementary Material 1.